AstraZeneca, GlaxoSmithKline infectious news
The EU's Innovative Medicines Initiative launched the NewDrugs4BadBugs grant program to fund development of new antibiotics against antibiotic-resistant bacteria, including products from GlaxoSmithKline and AstraZeneca. The program will also create an information hub to facilitate information sharing. The program will initially support Phase II and III trials of GSK's GSK1322322, an antibacterial agent that inhibits peptide deformyalse function. IMI will provide €88 million ($112.4 million), with an additional in-kind contribution of €103.7 million ($132.4 million) from industry partners. An additional €3 million ($3.8 million) from IMI and €5 million ($6.4 million) from industry will be available for projects to improve the efficiency of antibiotic clinical trials. ...